Cellectis S.A. (CLLS)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 16.7M | 35.2M | 10.4M | 5.8M |
| Gross Profit | 14.3M | 32.8M | 7.4M | 3.5M |
| Operating Income | -9.6M | 8.0M | -17.4M | -25.2M |
| Net Income | -23.7M | 589K | -26.3M | -17.8M |
| Diluted EPS | $nan | $0.01 | $-0.26 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 19.2M | 755K | 41.5M | 72.9M |
| Gross Profit | 10.7M | -6.7M | 32.3M | 63.2M |
| Operating Income | -89.7M | -97.3M | -59.6M | -33.1M |
| Net Income | -106.1M | -101.1M | -36.8M | -67.6M |
| Diluted EPS | $-2.33 | $-1.77 | $-0.41 | $-0.67 |